GRAIL, Inc. (NasdaqGS: GRAL)
Health Care · Biotechnology · US
$140.58
+6.01% today · +97.6% 1Y
GRAIL, Inc. (NasdaqGS: GRAL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.28B and employs 910 people.
Over the last twelve months the share price has gained 97.6%, trading between 41.50 and 166.48.
Tweenvest scores GRAIL, Inc. across four factors: quality 44/100, value 57/100. Its strongest factor is value.
GRAL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.28B
- Revenue (TTM)
- $165.26M
- P/E
- —
- EPS
- -9.75
- Dividend yield
- —
- Beta (5Y)
- 2.84
- 52-week high
- $166.48
- 52-week low
- $41.50
- Avg volume (3M)
- —
- Shares outstanding
- 44.67M
- Employees
- 910
- Next earnings
- —
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
- ISIN
- US3847471014
- Founded
- 2015
- Listed since
- Jun 12, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Gan & Lee Pharmaceuticals.SHSE: 603087 | $6.71B | CN¥75.52 | -2.43% |
| Iovance Biotherapeutics, Inc.NasdaqGM: IOVA | $6.62B | $14.62 | +9.84% |
| Grifols, S.A.BME: GRF | $6.62B | €9.88 | +2.02% |
| Immunovant, Inc.NasdaqGS: IMVT | $6.29B | $30.47 | +0.69% |
| Kodiak Sciences Inc.NasdaqGM: KOD | $6.26B | $99.87 | +5.74% |
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | $6.25B | $90.78 | -2.21% |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $79.78 | +1.31% |
| Biocon LimitedNSEI: BIOCON | $5.88B | Rs349.40 | -5.75% |
Figures last refreshed Oct 11, 2026.